Cyclazosin HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413402

CAS#: 146929-33-1 (HCl)

Description: Cyclazosin HCl is a hydrochloride composed of equimolar amounts of cyclazosin and hydrogen chloride. It has a role as an alpha1B-adrenoceptor antagonist. It contains a cyclazosin.

Chemical Structure

img
Cyclazosin HCl
CAS# 146929-33-1 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 413402
Name: Cyclazosin HCl
CAS#: 146929-33-1 (HCl)
Chemical Formula: C23H28ClN5O4
Exact Mass: 0.00
Molecular Weight: 473.960
Elemental Analysis: C, 58.29; H, 5.95; Cl, 7.48; N, 14.78; O, 13.50

Price and Availability

Size Price Availability Quantity
5mg USD 408 2 Weeks
25mg USD 1150 2 Weeks
Bulk inquiry

Related CAS #: 139953-73-4 (Free Base)   146929-33-1 (HCl)  

Synonym: Cyclazosin HCl; Cyclazosin hydrochloride

IUPAC/Chemical Name: ((4aR,8aS)-4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)octahydro-1(2H)-quinoxalinyl)(2-furyl)methanone hydrochloride (1:1)

InChi Key: SKDIDWRQDBIQBS-MCJVGQIASA-N

InChi Code: InChI=1S/C23H27N5O4.ClH/c1-30-19-12-14-15(13-20(19)31-2)25-23(26-21(14)24)28-10-9-27(16-6-3-4-7-17(16)28)22(29)18-8-5-11-32-18;/h5,8,11-13,16-17H,3-4,6-7,9-10H2,1-2H3,(H2,24,25,26);1H/t16-,17+;/m0./s1

SMILES Code: O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)[C@]4([H])CCCC[C@]14[H])C5=CC=CO5.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Soluble in DMSO 0.0 100.00

Preparing Stock Solutions

The following data is based on the product molecular weight 473.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Marucci G, Angeli P, Buccioni M, Gulini U, Melchiorre C, Sagratini G, Testa R, Giardinà D. (+)-Cyclazosin, a selective alpha1B-adrenoceptor antagonist: functional evaluation in rat and rabbit tissues. Eur J Pharmacol. 2005 Oct 17;522(1-3):100-7. doi: 10.1016/j.ejphar.2005.08.044. Epub 2005 Oct 6. PMID: 16213480.


2: Sagratini G, Buccioni M, Marucci G, Poggesi E, Skorski M, Costanzi S, Giardinà D. Chiral analogues of (+)-cyclazosin as potent α1B-adrenoceptor selective antagonist. Bioorg Med Chem. 2018 Jul 23;26(12):3502-3513. doi: 10.1016/j.bmc.2018.05.023. Epub 2018 May 17. PMID: 29784274; PMCID: PMC6008244.


3: Stam WB, Van der Graaf PH, Saxena PR. Functional characterisation of the pharmacological profile of the putative alpha1B-adrenoceptor antagonist, (+)-cyclazosin. Eur J Pharmacol. 1998 Nov 13;361(1):79-83. doi: 10.1016/s0014-2999(98)00735-3. PMID: 9851544.


4: Giardinà D, Polimanti O, Sagratini G, Angeli P, Gulini U, Marucci G, Melchiorre C, Poggesi E, Leonardi A. Searching for cyclazosin analogues as alpha(1B)-adrenoceptor antagonists. Farmaco. 2003 Jul;58(7):477-87. doi: 10.1016/s0014-827x(02)00025-3. PMID: 12818686.


5: Giardinà D, Crucianelli M, Melchiorre C, Taddei C, Testa R. Receptor binding profile of cyclazosin, a new alpha 1B-adrenoceptor antagonist. Eur J Pharmacol. 1995 Dec 4;287(1):13-6. doi: 10.1016/0014-2999(95)00471-7. PMID: 8666020.


6: Giardinà D, Sagratini G, Grelli M, Gulini U, Melchiorre C, Antolini L. Absolute configuration of the alpha (1B)-adrenoceptor antagonist (+)-cyclazosin. Farmaco. 2004 Dec;59(12):965-9. doi: 10.1016/j.farmac.2004.07.013. PMID: 15598431.


7: Sagratini G, Angeli P, Buccioni M, Gulini U, Marucci G, Melchiorre C, Leonardi A, Poggesi E, Giardinà D. Synthesis and alpha(1)-adrenoceptor antagonist activity of derivatives and isosters of the furan portion of (+)-cyclazosin. Bioorg Med Chem. 2007 Mar 15;15(6):2334-45. doi: 10.1016/j.bmc.2007.01.028. Epub 2007 Jan 19. PMID: 17276073.


8: Gao X, Abdelkarim H, Albee LJ, Volkman BF, Gaponenko V, Majetschak M. Partial agonist activity of α1-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3. PLoS One. 2018 Sep 24;13(9):e0204041. doi: 10.1371/journal.pone.0204041. PMID: 30248140; PMCID: PMC6152952.


9: Giardinà D, Crucianelli M, Romanelli R, Leonardi A, Poggesi E, Melchiorre C. Synthesis and biological profile of the enantiomers of [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-cis-octahydroquinoxalin- 1-yl]furan-2-ylmethanone (cyclazosin), a potent competitive alpha 1B- adrenoceptor antagonist. J Med Chem. 1996 Nov 8;39(23):4602-7. doi: 10.1021/jm960510x. PMID: 8917649.


10: Alsufyani HA, McCormick PA, Docherty JR. Both α1B- and α1A-adrenoceptor subtypes are involved in contractions of rat spleen. Pharmacol Rep. 2021 Feb;73(1):255-260. doi: 10.1007/s43440-020-00118-x. Epub 2020 Aug 28. PMID: 32860192.


11: Yoshiyama M, De Groat WC. Role of spinal alpha1-adrenoceptor subtypes in the bladder reflex in anesthetized rats. Am J Physiol Regul Integr Comp Physiol. 2001 May;280(5):R1414-9. doi: 10.1152/ajpregu.2001.280.5.R1414. PMID: 11294762.


12: Deluigi M, Morstein L, Schuster M, Klenk C, Merklinger L, Cridge RR, de Zhang LA, Klipp A, Vacca S, Vaid TM, Mittl PRE, Egloff P, Eberle SA, Zerbe O, Chalmers DK, Scott DJ, Plückthun A. Crystal structure of the α1B-adrenergic receptor reveals molecular determinants of selective ligand recognition. Nat Commun. 2022 Jan 19;13(1):382. doi: 10.1038/s41467-021-27911-3. PMID: 35046410; PMCID: PMC8770593.


13: Bexis S, Docherty JR. Role of alpha1-adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse. Br J Pharmacol. 2008 Feb;153(3):591-7. doi: 10.1038/sj.bjp.0707590. Epub 2007 Nov 26. PMID: 18037913; PMCID: PMC2241778.


14: Camargo LA, Saad WA, Camargo GP. Effects of subtypes alpha- and beta- adrenoceptors of the lateral hypothalamus on the water and sodium intake induced by angiotensin II injected into the subfornical organ. Brain Res. 2000 Oct 27;881(2):176-81. doi: 10.1016/s0006-8993(00)02840-7. PMID: 11036156.


15: Proudman RGW, Pupo AS, Baker JG. The affinity and selectivity of α-adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D-adrenoceptors. Pharmacol Res Perspect. 2020 Aug;8(4):e00602. doi: 10.1002/prp2.602. PMID: 32608144; PMCID: PMC7327383.


16: Gotoh Y, Andoh T, Kuraishi Y. Noradrenergic regulation of itch transmission in the spinal cord mediated by α-adrenoceptors. Neuropharmacology. 2011 Sep;61(4):825-31. doi: 10.1016/j.neuropharm.2011.05.030. Epub 2011 Jun 7. PMID: 21664915.


17: Buccioni M, Kandhavelu M, Angeli P, Cristalli G, Dal Ben D, Giardinà D, Lambertucci C, Lammi C, Volpini R, Marucci G. Identification of alpha1-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens. Eur J Pharmacol. 2009 Jan 14;602(2-3):388-94. doi: 10.1016/j.ejphar.2008.10.067. Epub 2008 Nov 14. PMID: 19041301.


18: Giardinà D, Gulini U, Massi M, Piloni MG, Pompei P, Rafaiani G, Melchiorre C. Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on alpha-blocking activity. J Med Chem. 1993 Mar 19;36(6):690-8. doi: 10.1021/jm00058a005. PMID: 8096245.


19: Marinese D, Patel R, Walden PD. Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate. 2003 Feb 15;54(3):230-7. doi: 10.1002/pros.10170. PMID: 12518328.


20: Errasti AE, Werneck de Avellar MC, Daray FM, Tramontano J, Luciani LI, Lina Bard MJ, Maróstica E, Rothlin RP. Human umbilical vein vasoconstriction induced by epinephrine acting on alpha1B-adrenoceptor subtype. Am J Obstet Gynecol. 2003 Nov;189(5):1472-80. doi: 10.1067/s0002-9378(03)00646-x. PMID: 14634588.